Oncolytics gets patent for preventing reovirus recognition by immune system

By E. Janene Geiss

Philadelphia, March 27 - Oncolytics Biotech Inc. has been granted U.S. Patent 7,014,847 entitled "Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders."

The claims describe methods for preventing reovirus recognition by the host immune system while concurrently or subsequently administering reovirus, resulting in substantial lysis of the proliferating cells, according to a company news release.

"The claims in this U.S. patent allow manipulation of the immune system that may enhance the effectiveness of Reolysin treatment," Matt Coffey, chief scientific officer of Oncolytics, said in the release.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

The company's clinical program includes a variety of phase 1 and phase 1/2 human trials using Reolysin, its proprietary formulation of the human reovirus, alone and in combination with radiation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.